{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T09:56:53Z","timestamp":1765274213411,"version":"3.46.0"},"reference-count":17,"publisher":"Walter de Gruyter GmbH","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2017-0008_s_005_w2aab3b7b3b1b6b1aab1c15b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neutropenia and thrombocytopenia are well-recognised complications of systemic chemotherapy. In cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC), the interplay between surgical factors and systemic toxicity of chemotherapeutics must be considered when considering post-operative haematological outcomes. We sought to quantify the incidence of these events in cytoreductive surgery and HIPEC at our institution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0008_s_006_w2aab3b7b3b1b6b1aab1c15b2Aa\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a single centre, a retrospective cohort study of 50 consecutive patients who underwent cytoreductive surgery and HIPEC from 2002 to 2015. Routine haematological data were analysed and complications classified according to CTCAE 4.0. Subgroup analysis was undertaken to compare those who received or not perioperative systemic chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0008_s_007_w2aab3b7b3b1b6b1aab1c15b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The rate of all-grade post-procedure neutropenia was 4\u2006% (n=2\/50); one grade 1, and one grade 4 neutropenia. The patient with grade 4 neutropenia died day 57 post-operatively, despite subsequent growth factor support. Eight percent (n=4\/50) of patients had thrombocytopenia preoperatively. The overall rate of post-procedure thrombocytopenia was 46\u2006% with grade 3\u20134 thrombocytopenia of 4\u2006%. If not present preoperatively, thrombocytopenia onset was on day 1 or 2 post-operatively, with a median duration of 3 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2017-0008_s_008_w2aab3b7b3b1b6b1aab1c15b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Intraperitoneal delivery of chemotherapy as HIPEC can cause haematological toxicity with potentially fatal outcomes. However, the incidence of neutropenia and thrombocytopenia after CRS and HIPEC is low.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2017-0008","type":"journal-article","created":{"date-parts":[[2017,8,12]],"date-time":"2017-08-12T06:01:43Z","timestamp":1502517703000},"page":"137-141","source":"Crossref","is-referenced-by-count":6,"title":["Neutropenia and thrombocytopenia after cytoreductive surgery and heated intraperitoneal chemotherapy"],"prefix":"10.1515","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7265-8782","authenticated-orcid":false,"given":"Ben","family":"Finlay","sequence":"first","affiliation":[{"name":"Department of Surgery , The Queen Elizabeth Hospital , 28 Woodville Road , Woodville South SA 5011 , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Price","sequence":"additional","affiliation":[{"name":"Department of Haematology and Oncology and University of Adelaide , The Queen Elizabeth Hospital , Woodville South , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hewett","sequence":"additional","affiliation":[{"name":"Department of Surgery , The Queen Elizabeth Hospital , 28 Woodville Road , Woodville South SA 5011 , Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2017,8,12]]},"reference":[{"key":"2025120909192903973_j_pp-2017-0008_ref_001_w2aab3b7b3b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Hadi R, Saunders V, Utkina O, Clingan P, Kam P, Links M et al. Review of patients with peritoneal malignancy treated with peritonectomy and heated intraperitoneal chemotherapy. ANZ J Surg 2006;76:156\u2013161.","DOI":"10.1111\/j.1445-2197.2006.03579.x"},{"key":"2025120909192903973_j_pp-2017-0008_ref_002_w2aab3b7b3b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Chalret Du Rieu Q, White-Koning M, Picaud L, Lochon I, Marsili S, Gladieff L et al. Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: Correlation between oxaliplatin exposure and thrombocytopenia. Cancer Chemother Pharmacol 2014;74:571\u2013582.","DOI":"10.1007\/s00280-014-2525-6"},{"key":"2025120909192903973_j_pp-2017-0008_ref_003_w2aab3b7b3b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Valenzuela B, Nalda-Molina R, Bretcha-Boix P, Escudero-Ortiz V, Duart MJ, Carbonell V et al. Pharmacokinetic and pharmacodynamic analysis of hyperthermic intraperitoneal oxaliplatin-induced neutropenia in subjects with peritoneal carcinomatosis. Aaps J 2011;13:72\u201382.","DOI":"10.1208\/s12248-010-9249-2"},{"key":"2025120909192903973_j_pp-2017-0008_ref_004_w2aab3b7b3b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Klaver C, Musters G, Bemelman W, Punt C, Verwaal V, Dijkgraaf M et al. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer 2015;15.","DOI":"10.1186\/s12885-015-1430-7"},{"key":"2025120909192903973_j_pp-2017-0008_ref_005_w2aab3b7b3b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Gonzalez-Moreno S, Gonzales-Bayon L, Ortega-Perez G. Hyperthermic intraperitoneal chemotherapy: Rationale and technique. World J Gastrointest Oncol 2010;2:68\u201375.","DOI":"10.4251\/wjgo.v2.i2.68"},{"key":"2025120909192903973_j_pp-2017-0008_ref_006_w2aab3b7b3b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH. Peritonectomy Procedures. Ann Surg 1995;221:29\u201342.","DOI":"10.1097\/00000658-199501000-00004"},{"key":"2025120909192903973_j_pp-2017-0008_ref_007_w2aab3b7b3b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Perez-Ruixo C, Valenzuela B, Peris JE, Bretcha-Boix P, Escudero-Ortiz V, Farre-Alegre J et al. Neutrophil dynamics in peritoneal carcinomatosis patients treated with cytoreductive surgery and hyperthermic intraperitoneal oxaliplatin. Clin Pharmacokinet 2013;52:1111\u20131125.","DOI":"10.1007\/s40262-013-0092-3"},{"key":"2025120909192903973_j_pp-2017-0008_ref_008_w2aab3b7b3b1b6b1ab2b1b8Aa","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v4.0. United States of America: National Cancer Institute, National Institutes of Health, Department of Health and Human Services, 2009."},{"key":"2025120909192903973_j_pp-2017-0008_ref_009_w2aab3b7b3b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Perez-Ruixo C, Valenzuela B, Peris JE, Bretcha-Boix P, Escudero-Ortiz V, Farre-Alegre J et al. Platelet dynamics in peritoneal carcinomatosis patients treated with cytoreductive surgery and hyperthermic intraperitoneal oxaliplatin. Aaps J 2016;18:239\u2013250.","DOI":"10.1208\/s12248-015-9839-0"},{"key":"2025120909192903973_j_pp-2017-0008_ref_010_w2aab3b7b3b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Hompes D, D\u2019Hoore A, Van Cutsem E, Fieuws S, Ceelen W, Peeters M et al. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: A Belgian multicentre prospective phase II clinical study. Ann Surg Oncol 2012;19:2186\u20132194.","DOI":"10.1245\/s10434-012-2264-z"},{"key":"2025120909192903973_j_pp-2017-0008_ref_011_w2aab3b7b3b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Hompes D, D\u2019Hoore A, Wolthuis A, Fieuws S, Mirck B, Bruin S et al. The use of Oxaliplatin or Mitomycin C in HIPEC Treatment for Periotoneal Carcinomatosis from Colorectal Cancer: A Comparative Study. J Surg Oncol 2014;109:527\u2013532.","DOI":"10.1002\/jso.23546"},{"key":"2025120909192903973_j_pp-2017-0008_ref_012_w2aab3b7b3b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Lambert LA, Armstrong TS, Lee JJ, Liu S, Katz MH, Eng C et al. Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol 2009;16:2181\u20132187.","DOI":"10.1245\/s10434-009-0523-4"},{"key":"2025120909192903973_j_pp-2017-0008_ref_013_w2aab3b7b3b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Glockzin G, Breitenburch P, Schlitt H, Piso P. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: A matched-pair analysis. J Surg Oncol 2013;107:574\u2013578.","DOI":"10.1002\/jso.23228"},{"key":"2025120909192903973_j_pp-2017-0008_ref_014_w2aab3b7b3b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Kemmel V, Mercoli HA, Meyer N, Brumaru D, Romain B, Lessinger JM et al. Mitomycin C Pharmacokinetics as predictor of severe neutropenia in hyperthermic intraperitoneal therapy. Ann Surg Oncol 2015;22:873\u2013879.","DOI":"10.1245\/s10434-015-4679-9"},{"key":"2025120909192903973_j_pp-2017-0008_ref_015_w2aab3b7b3b1b6b1ab2b1c15Aa","unstructured":"Newton AD, Bartlett EK, Karakousis GC. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A review of factors contributing to morbidity and mortality. J Gastrointest Oncol 2016;7:99\u2013111."},{"key":"2025120909192903973_j_pp-2017-0008_ref_016_w2aab3b7b3b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Jardim DL, Rodrigues CA, Novis YA, Rocha VG, Hoff PM. Oxaliplatin-related thrombocytopenia. Ann Oncol 2012;23:1937\u20131942.","DOI":"10.1093\/annonc\/mds074"},{"key":"2025120909192903973_j_pp-2017-0008_ref_017_w2aab3b7b3b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Schiebe M, Hoffmann W, Belka C, Bamberg M. Mitomycin C-related hemolytic uremic syndrome in cancer patients. Anticancer Drugs 1998;9:433\u2013435.","DOI":"10.1097\/00001813-199806000-00010"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/2\/3\/article-p137.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0008\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0008\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T09:53:34Z","timestamp":1765274014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0008\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,12]]},"references-count":17,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,9,1]]},"published-print":{"date-parts":[[2017,8,31]]}},"alternative-id":["10.1515\/pp-2017-0008"],"URL":"https:\/\/doi.org\/10.1515\/pp-2017-0008","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"type":"electronic","value":"2364-768X"},{"type":"print","value":"2364-7671"}],"subject":[],"published":{"date-parts":[[2017,8,12]]}}}